Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
0.02 (0.43%)
At close: May 20, 2022 4:00 PM
0.20 (4.25%)
After-hours:May 20, 2022 5:13 PM EDT

Total Valuation

Humacyte has a market cap or net worth of $485.15 million. The enterprise value is $330.01 million.

Market Cap485.15M
Enterprise Value330.01M

Important Dates

The latest earnings date was Friday, May 13, 2022, before market open.

Last Earnings DateMay 13, 2022
Ex-Dividend Daten/a

Share Statistics

Humacyte has 103.01 million shares outstanding. The number of shares has increased by 1,653.35% in one year.

Shares Outstanding103.01M
Shares Change (YoY)+1,653.35%
Shares Change (QoQ)+157.70%
Owned by Insiders (%)49.75%
Owned by Institutions (%)11.61%

Valuation Ratios

PE Ration/a
Forward PEn/a
PS Ratio361.78
PB Ratio4.67
P/FCF Ration/a
PEG Ration/a
Financial Ratio History

Enterprise Valuation

EV / Earningsn/a
EV / Sales246.10
EV / EBITn/a
EV / FCFn/a

Financial Position

The company has a current ratio of 19.45, with a Debt / Equity ratio of 0.49.

Current Ratio19.45
Quick Ratio19.18
Debt / Equity0.49
Debt / EBITDAn/a
Debt / FCFn/a

Financial Efficiency

Return on Equity (ROE)n/a
Return on Assets (ROA)-11.00%
Return on Capital (ROIC)-21.20%
Revenue Per Employee$9,248
Profits Per Employee-$179,366
Employee Count145
Asset Turnover0.01
Inventory Turnovern/a


Income Taxn/a
Effective Tax Raten/a

Stock Price Statistics

The stock price has decreased by -50.90% in the last 52 weeks.

Beta (1Y)n/a
52-Week Price Change-50.90%
50-Day Moving Average6.48
200-Day Moving Average7.18
Average Volume (30 Days)376,865

Short Selling Information

The latest short interest is 5.89 million, so 5.71% of the outstanding shares have been sold short.

Short Interest5.89M
Short % of Shares Out5.71%
Short % of Float11.55%
Short Ratio (days to cover)18.25

Income Statement

In the last 12 months, Humacyte had revenue of $1.34 million and -26.01 million in losses. Earnings per share was -$0.41.

Gross Profit1.34M
Operating Income-83.20M
Net Income-26.01M
Earnings Per Share (EPS)-$0.41
Full Income Statement

Balance Sheet

The company has $206.22 million in cash and $51.08 million in debt, giving a net cash position of $155.14 million or $1.51 per share.

Cash & Cash Equivalents206.22M
Total Debt51.08M
Net Cash155.14M
Net Cash Per Share$1.51
Book Value103.89M
Book Value Per Share1.01
Working Capital198.53M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$85.44 million and capital expenditures -$213,000, giving a free cash flow of -$85.66 million.

Operating Cash Flow-85.44M
Capital Expenditures-213,000
Free Cash Flow-85.66M
FCF Per Sharen/a
Full Cash Flow Statement


Gross margin is 100.00%, with operating and profit margins of -6,204.47% and -1,939.45%.

Gross Margin100.00%
Operating Margin-6,204.47%
Pretax Marginn/a
Profit Margin-1,939.45%
EBITDA Margin-932.66%
EBIT Margin-1,548.17%
FCF Margin-6,387.55%

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Sharen/a
Dividend Yieldn/a
Earnings Yield-5.36%
FCF Yield-17.66%
Dividend Growth (YoY)n/a
Payout Ration/a
Buyback Yield-1,653.35%
Shareholder Yield-1,653.35%
Dividend Details

Analyst Forecast

The average price target for Humacyte is $14.96, which is 217.62% higher than the current price. The consensus rating is "Buy".

Price Target$14.96
Price Target Difference217.62%
Analyst ConsensusBuy
Analyst Count12
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Daten/a
Split Typen/a
Split Ration/a